^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LAMTOR5 (Late Endosomal/Lysosomal Adaptor)

    i
    Other names: LAMTOR5, Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 5, XIP, HBXIP, Late Endosomal/Lysosomal Adaptor And MAPK And MTOR Activator 5, Hepatitis B Virus X-Interacting Protein (9.6kD), Hepatitis B Virus X Interacting Protein, Ragulator Complex Protein LAMTOR5, HBV X-Interacting Protein, HBx-Interacting Protein, MGC71071, Hepatitis B Virus X-Interacting Protein, HBX-Interacting Protein
    17d
    Systematic fusion transcript discovery in mantle cell lymphoma using long-read sequencing. (PubMed, bioRxiv)
    Since the origin, significance and impact of many fusion transcripts remain unknown, our results support using an unbiased approach to identify fusion transcripts. This will help us to fully comprehend the complexity of the human transcriptome in normal biology and in disease.
    Journal
    |
    LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • RBM15 (RNA Binding Motif Protein 15)
    2ms
    LAMTOR5 promotes hepatoma growth in mice by disrupting LC3-p62-mediated autophagy and preventing p62 proteasome degradation. (PubMed, Acta Pharmacol Sin)
    Lenvatinib, a multi-receptor tyrosine kinase inhibitor, significantly suppressed HCC growth in vitro and in vivo by downregulating LAMTOR5 and p62 expression. We conclude that LAMTOR5-mediated p62 stabilization is a novel HCC growth mechanism, targeting this axis as a promising therapeutic strategy.
    Preclinical • Journal
    |
    LAMTOR5 (Late Endosomal/Lysosomal Adaptor)
    |
    Lenvima (lenvatinib)
    4ms
    Identification and characterization of lLF2 as a prognostic biomarker in HER2-positive breast cancer using Mendelian randomization and machine learning. (PubMed, Discov Oncol)
    ILF2 is biologically and clinically important in HER2-positive breast cancer, and its high expression is linked with tumor immune escape and increased resistance to chemotherapeutic agents. Future studies should further explore the mechanism and application of ILF2 as a potential therapeutic target.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • SLC16A3 (Solute Carrier Family 16 Member 3) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
    |
    HER-2 positive • HER-2 expression
    1year
    Increased expression of HBXIP (LAMTOR5) predicts poor prognosis and is correlated with immune-cell infiltration in glioma. (PubMed, Transl Cancer Res)
    Its high expression is associated with poor prognosis, which may potentially be linked to immune escape and immune cell infiltration. HBXIP is a potential biomarker of prognostic and immune infiltration in glioma.
    Journal • IO biomarker • Immune cell
    |
    LAMTOR5 (Late Endosomal/Lysosomal Adaptor)
    over1year
    LAMTOR5-AS1 Regulates Chemotherapy-induced Oxidative Stress via the miR-34a-3p/SIRT1/HNF4A Axis in Osteosarcoma Cells. (PubMed, Curr Med Chem)
    These findings offer new insights into lncRNA-mediated drug resistance in cancer and may serve as potential biomarkers for cancer therapy.
    Journal
    |
    MIR34A (MicroRNA 34a-5p) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • HNF1A (HNF1 Homeobox A)
    over1year
    Oncoprotein LAMTOR5-mediated CHOP silence via DNA hypermethylation and miR-182/miR-769 in promotion of liver cancer growth. (PubMed, Acta Pharmacol Sin)
    Notably, lenvatinib, a first-line targeted therapy for liver cancer, could target the LAMTOR5/CHOP axis to prevent liver cancer progression. Accordingly, LAMTOR5-mediated silencing of CHOP via the regulation of ER stress-related apoptosis promotes liver cancer growth, providing a theoretical basis for the use of lenvatinib for the treatment of liver cancer.
    Journal
    |
    DNMT1 (DNA methyltransferase 1) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • MIR182 (MicroRNA 182) • MIR769 (MicroRNA 769)
    |
    Lenvima (lenvatinib)
    over2years
    Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer. (PubMed, Front Mol Biosci)
    Collectively, 15 crucial CC genes showing indicative values for prognosis and immune microenvironment of OC were comprehensively identified. These findings provided insight into the further exploration of the molecular mechanisms of OC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IL16 (Interleukin 16) • IL33 (Interleukin 33) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor)
    |
    PD-L1 expression • CTLA4 expression
    almost3years
    Non-coding RNAs are correlated to TGF-β receptor type 2 in patients with colorectal cancer. (PubMed, J Gene Med)
    We suggested that the miR20a-5p is inversely related to lncRNA LAMTOR5-AS so that it may be involved in the regulation of TGFBR2 expression level in CRC patients.
    Journal
    |
    TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • MIR20A (MicroRNA 20a)
    over3years
    The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma. (PubMed, Front Immunol)
    The possible functions of PRGs in the TME, clinicopathological characteristics, and prognosis were established in our investigation of PRGs in OS. These findings may aid in our understanding of PRGs in OS as well as provide a novel way for prognostic evaluation and the creation of more effective immunotherapy treatments.
    Journal • IO biomarker
    |
    LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • TP63 (Tumor protein 63) • MIR23A (MicroRNA 23a)
    over3years
    LncRNA LAMTOR5-AS1 sponges miR-210-3p and regulates cervical cancer progression. (PubMed, J Obstet Gynaecol Res)
    LAMTOR5-AS1 sponges miR-210-3p and modulates the progression of cervical cancer, which predict the prognosis of cervical cancer patients.
    Journal
    |
    LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • MIR210 (MicroRNA 210)
    |
    LAMTOR5 overexpression